The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Dec. 6, 9:20 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #55. OPKO Health Laboratorio Arama de Uruguay Limitada

Acquirer: OPKO Health (NASDAQ:OPK)
Acquiree: Laboratorio Arama de Uruguay Limitada
Details: OPKO Health, Inc. (NYSE:OPK) has entered into an agreement to acquire Laboratorio Arama de Uruguay Limitada ("Arama"). Domiciled in Montevideo, Uruguay, Arama will add to our growing South American presence in the important Mercosur economic region while further complementing our business activities in Chile, Mexico and Brazil. The transaction is expected to close in January 2014.

Opko Health is a healthcare company. Co.'s reportable segments are: diagnostics, which consists of the clinical laboratory operations of its subsidiary, BioReference Laboratories, Inc. (BioReference), as well as its point-of-care operations; and pharmaceutical, which consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Through BioReference, Co. provides laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare.

OPK SEC Filing Email Alerts Service


Open the OPK Page at The Online Investor »

Company Name: 
OPKO Health Inc
Website: 
www.opko.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding OPK: 
30
Total Market Value Held by ETFs: 
$176.67M
Total Market Capitalization: 
$1.13B
% of Market Cap. Held by ETFs: 
15.66%
 

Open the OPK Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree OPK Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.50 out of 4)
53rd percentile
(ranked higher than approx. 53% of all stocks covered)

Analysts' Target Price:
OPK Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 55 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.